# Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy

> **NCT05919212** · NA · UNKNOWN · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 22 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment

## Key facts

- **NCT ID:** NCT05919212
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2026-02-01
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05919212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05919212, "Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05919212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*